Abstract
BACKGROUND/AIM: Head and neck squamous cell carcinoma affects nearly 500,000 people annually. Augmenting PPARγ functional activation is linked with multiple anti-carcinogenic processes in aerodigestive cell lines and animal models. PPARγ/RXRα heterodimers may be key partners in this activation.
MATERIALS AND METHODS: CA 9-22 and NA cell lines were treated with the PPARγ agonist ciglitazone and/or the RXRα agonist 9-cis-retinoic acid. PPARγ functional activation, cellular proliferation, apoptosis activity, and phenotype were subsequently analyzed.
RESULTS: Ciglitazone and 9-cis-retinoic acid independently activated PPARγ and down-regulated the carcinogenic phenotype in vitro. Combination treatment significantly augmented these effects, further decreasing proliferation (p<0.0001), and increasing PPARγ functional activation (p<0.0001), apoptosis (p<0.05), and adipocyte differentiation markers (p<0.0001).
CONCLUSION: The efficacy of the combination of ciglitazone and 9-cis-retinoic acid afforded lowering treatment concentrations while maintaining desired therapeutic outcomes, optimistically supporting the feasibility and practicality of this novel treatment option.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3071-3080 |
| Number of pages | 10 |
| Journal | Anticancer Research |
| Volume | 40 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2020 |
Bibliographical note
Publisher Copyright:© 2020 International Institute of Anticancer Research. All rights reserved.
Keywords
- 9-cis-retinoic acid
- Ciglitazone
- Head
- Neck squamous carcinoma
- PPARγ
- Retinoids
- Thiazolidinedione
- Retinoids/pharmacology
- PPAR gamma/metabolism
- Humans
- Survival Rate
- Mouth Neoplasms/drug therapy
- Thiazolidinediones/pharmacology
PubMed: MeSH publication types
- Journal Article
